

09/4/6, 812
WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

starting with: REPL\$(REPLOGLE-ET-AL).P27-P83.

Search Results -

Terms	Documents
adenovir\$ same selecti\$ near5 repl\$ same E2F near5 (RB or Rb)	0

Database:

US Patents Full Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

[Refine Search:](#)adenovir\$ same selecti\$ near5 repl\$ same
E2F near5 (RB or Rb)[Clear](#)**Search History**

Today's Date: 10/20/2000

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	adenovir\$ same selecti\$ near5 repl\$ same E2F near5 (RB or Rb)	0	<u>L5</u>
USPT	adenovir\$ same selecti\$ near5 repl\$ same (p53 or Rb or TGF)near5 promot\$	0	<u>L4</u>
USPT	adenovir\$ same selecti\$ near5 repl\$ same (p53 or Rb or TGF)	9	<u>L3</u>
USPT	adenovir\$ same selecti\$ near5 repl\$ same pathway near5 respon\$	0	<u>L2</u>
USPT	adenovir\$ same selecti\$ near5 repl\$	37	<u>L1</u>

FILE 'HOME' ENTERED AT 08:32:19 ON 20 OCT 2000

=> file medline, scisearch, biosis, embase, caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 08:32:37 ON 20 OCT 2000

FILE 'SCISEARCH' ENTERED AT 08:32:37 ON 20 OCT 2000
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'BIOSIS' ENTERED AT 08:32:37 ON 20 OCT 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 08:32:37 ON 20 OCT 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 08:32:37 ON 20 OCT 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s adeno? (p) selec? (s) repli? (p) E2F (s)RB or Rb

(S) IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s adeno? (p) selec? (s) repli?

L1 1018 ADENO? (P) SELEC? (S) REPLI?

=> s E2F (s) RB or Rb

L2 92048 E2F (S) RB OR RB

=> s L1 and L2

L3 18 L1 AND L2

=> s (p53 or RB or Rb or TGF) (s) promoter

L4 9713 (P53 OR RB OR Rb OR TGF) (S) PROMOTER

=> s L3 and L4

L5 1 L3 AND L4

=> display total ibib abs L5

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 2000:260544 CAPLUS
DOCUMENT NUMBER: 132:289626
TITLE: Recombinant adenoviral vectors expressing viral

INVENTOR(S): replication repressors controlled by a pathway-responsive promoter for therapeutic usage
PATENT ASSIGNEE(S): Ramachandra, Muralidhara; Shabram, Paul W.
SOURCE: Canji, Inc., USA
PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000022137	A2	20000420	WO 1999-US21452	19991014
WO 2000022137	A3	20000803		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9963915	A1	20000501	AU 1999-63915	19991014
PRIORITY APPLN. INFO.:			US 1998-172686	19981015
			WO 1999-US21452	19991014

AB Recombinant **adenoviral** vectors expressing viral replication repressors controlled by a pathway-responsive promoter is described for therapeutic usage. These viral vectors **replicate selectively** in response to the intracellular conditions of the target cell. These repressor genes controlled by **E2F** and **Rb**, or **p53**, or **TGF.beta.** responsive-promoters are **selectively** expressed in response to the intracellular conditions of the target cells and subsequently inhibits viral vector **replication** in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate for therapeutic purposes. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concn. of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.